Patient-Reported Outcome Questionnaire Shows Promise for Monitoring ITP – ASH Clinical News
Patient-Reported Outcome Questionnaire Shows Promise for Monitoring ITP – Bleeding Disorders, Literature Scan, News – ASH Clinical News
Related Articles
David John Lewis, MD: Ibrutinib and Rituximab in Older Patients with Mantle Cell Lymphoma
ASH Clinical News Editor-in-Chief Aaron Gerds, MD, interviews David John Lewis, MD, at the 66th ASH Annual Meeting and Exposition to discuss his abstract on…
BOVen Regimen NCCN-Approved Option for TP53-Mutated MCL | ASH Clinical News | American Society of Hematology
Leah Lawrence is a freelance health writer and editor based in Delaware. The three-drug regimen of zanubrutinib, obinutuzumab, and venetoclax—dubbed the BOVen regimen—is an effective…
Significant Proportion of Cancer Trials Exclude Individuals with Duffy Null–Associated Neutrophil Count, Study Finds | ASH Clinical News | American Society of Hematology
Anna Azvolinsky, PhD, is a freelance medical and science journalist based in New York City. Many phase III cancer clinical trials exclude individuals with absolute…
Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Respond Well to Asciminib, Dasatinib | ASH Clinical News | American Society of Hematology
Lara C. Pullen, PhD, is a freelance medical writer in Chicago, Illinois. Historically, hematologists have feared Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) because of…
MRD-Guided Therapy Improves Quality of Life for Patients With CLL | ASH Clinical News | American Society of Hematology
Anna Azvolinsky is a science and health journalist based in New York City. Time-limited treatment with ibrutinib plus venetoclax in patients with relapsed or refractory…
Eliminating Modifiable Risk Factors Lowers Bleeding Risk in Patients With Cancer, VTE, Study Finds | ASH Clinical News | American Society of Hematology
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. Anemia and hypertension were the two modifiable risk factors most closely related…
Bispecific Antibody Elicits High Responses Among Patients With Heavily Pretreated CLL | ASH Clinical News | American Society of Hematology
Anna Azvolinsky is a science and health journalist based in New York City. Patients with heavily pretreated, relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL)…
Considerable Morbidity and Mortality Seen in AIHA, Long-Term Study Finds | ASH Clinical News | American Society of Hematology
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. In a long-term look at the clinical features and course of disease…
CAR-T Produces Good Long-Term Outcomes in R/R CLL, Analysis Finds | ASH Clinical News | American Society of Hematology
Thomas R. Collins is a medical journalist based in West Palm Beach, Florida. Patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) treated with…
Reduced Dose of Direct Oral Anticoagulants May Reduce Bleeding, Health Care Usage in VTE Management | ASH Clinical News | American Society of Hematology
Khylia Marshall is a freelance journalist based in Tucson, Arizona. On Sunday, December 8 at the 66th American Society of Hematology (ASH) Annual Meeting and…